EBS vs. MNKD, IRWD, INVA, OPK, LXRX, AGEN, VNDA, XOMA, CDXS, and ACHV
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include MannKind (MNKD), Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), OPKO Health (OPK), Lexicon Pharmaceuticals (LXRX), Agenus (AGEN), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Codexis (CDXS), and Achieve Life Sciences (ACHV). These companies are all part of the "biotechnology" industry.
Emergent BioSolutions (NYSE:EBS) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
MannKind received 161 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.45% of users gave Emergent BioSolutions an outperform vote while only 59.87% of users gave MannKind an outperform vote.
Emergent BioSolutions has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, MannKind has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.
In the previous week, Emergent BioSolutions had 8 more articles in the media than MannKind. MarketBeat recorded 9 mentions for Emergent BioSolutions and 1 mentions for MannKind. Emergent BioSolutions' average media sentiment score of 0.75 beat MannKind's score of 0.00 indicating that Emergent BioSolutions is being referred to more favorably in the media.
Emergent BioSolutions presently has a consensus price target of $5.00, indicating a potential downside of 19.22%. MannKind has a consensus price target of $8.00, indicating a potential upside of 71.31%. Given MannKind's stronger consensus rating and higher probable upside, analysts plainly believe MannKind is more favorable than Emergent BioSolutions.
MannKind has lower revenue, but higher earnings than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.
78.4% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 1.2% of Emergent BioSolutions shares are held by company insiders. Comparatively, 3.0% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
MannKind has a net margin of 3.78% compared to Emergent BioSolutions' net margin of -47.68%. MannKind's return on equity of -3.35% beat Emergent BioSolutions' return on equity.
Summary
MannKind beats Emergent BioSolutions on 12 of the 18 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
